莫索尼定对健康男性志愿者醛固酮/肾素比值的影响
研究纳入20名血压正常、未用药的男性志愿者,测量基线及莫索尼定0.2 mg/d治疗1周和0.4 mg/d治疗5周后的血浆醛固酮、直接肾素浓度、血浆肾素活性及醛固酮/肾素比值。结果显示莫索尼定虽显著降低收缩压和舒张压,但醛固酮/肾素比值无显著变化,可能适用于筛查原发性醛固酮增多症时维持血压控制。
要点
- 莫索尼定0.2 mg/d治疗1周和0.4 mg/d治疗5周后,醛固酮/肾素比值无显著变化。
- 莫索尼定治疗期间收缩压和舒张压均显著下降,但醛固酮、直接肾素浓度和血浆肾素活性无显著改变。
- 莫索尼定可能适用于筛查原发性醛固酮增多症时维持高血压控制。
核心结论
- 莫索尼定与醛固酮/肾素比值无显著变化相关,因此当筛查原发性醛固酮增多症时,可能是一个维持高血压控制的好选择。
研究设计与样本
- 研究纳入20名血压正常、未用药的男性志愿者,在基线以及莫索尼定0.2 mg/d治疗1周和0.4 mg/d治疗5周后,于坐位、上午中间时间测量血浆醛固酮(高效液相色谱-串联质谱法)、直接肾素浓度、血浆肾素活性、皮质醇、电解质和肌酐,以及尿醛固酮、皮质醇、电解质和肌酐。
主要发现
- 与基线相比,莫索尼定治疗1周和6周后,尽管收缩压和舒张压均显著下降,但血浆醛固酮中位数分别为134(范围90-535)pmol/L、135(98-550)pmol/L和130(90-500)pmol/L,无显著变化。
- 直接肾素浓度中位数分别为20(10-37)mU/L、20(11-35)mU/L和22(8-40)mU/L,无显著变化。
- 血浆肾素活性中位数分别为2.2(1.0-3.8)ng/mL/h、2.0(1.2-4.1)ng/mL/h和2.1(1.0-3.2)ng/mL/h,无显著变化。
- 使用直接肾素浓度的醛固酮/肾素比值中位数分别为8.0(4.4-14.4)、8.8(4.2-15.9)和7.7(4.3-22.4),无显著变化;使用血浆肾素活性的醛固酮/肾素比值中位数分别为73(36-218)、73(32-194)和84(32-192),无显著变化。
- 任何尿液测量指标均无变化。
临床怎么用
- 作者认为,莫索尼定可能适用于筛查原发性醛固酮增多症时维持高血压控制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The most popular screening test for primary aldosteronism is the plasma aldosterone/renin ratio (ARR). Medications, dietary sodium, posture, and time of day all affect renin and aldosterone levels and can result in false-negative or false-positive ARRs if not controlled. Most antihypertensive medications affect the ARR and can interfere with interpretation of results. To our knowledge, no study has been undertaken to evaluate the effects of moxonidine on the ARR. METHODS: Normotensive, nonmedicated male volunteers (n = 20) underwent measurement (seated, midmorning) of plasma aldosterone (by high-performance liquid chromatography-tandem mass spectrometry), direct renin concentration (DRC), plasma renin activity (PRA), cortisol, electrolytes and creatinine; and urinary aldosterone, cortisol, electrolytes and creatinine at baseline and after 1 week of moxonidine at 0.2 mg/d and a further 5 weeks at 0.4 mg/d. RESULTS: Compared with baseline, despite the expected significant falls in both systolic and diastolic blood pressure, levels of plasma aldosterone [median, 134 (range, 90 to 535) pmol/L], DRC [20 (10 to 37) mU/L], PRA [2.2 (1.0-3.8) ng/mL/h], and ARR using either DRC [8.0 (4.4 to 14.4)] or PRA [73 (36 to 218)] were not significantly changed after either 1 [135 (98-550) pmol/L, 20 (11-35) mU/L, 2.0 (1.2-4.1) ng/mL/h, 8.8 (4.2 to 15.9), and 73 (32-194), respectively] or 6 weeks [130 (90-500) pmol/L, 22 (8 to 40) mU/L, 2.1 (1.0 to 3.2) ng/mL/h, 7.7 (4.3 to 22.4), and 84 (32 to 192), respectively] of moxonidine. There were no changes in any urinary measurements. CONCLUSION: Moxonidine was associated with no significant change in the ARR and may therefore be a good option for maintaining control of hypertension when screening for primary aldosteronism.
引用
- Ahmed AH, Gordon RD, Ward G, et al. Effect of Moxonidine on the Aldosterone/Renin Ratio in Healthy Male Volunteers. J Clin Endocrinol Metab. 2017. PMID: 28324033. doi:10.1210/jc.2016-3821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。